Elpis Biopharmaceuticals Showcases Preclinical Data from its Transformative Multi-functional Immuno-Oncology Programs at 2022 AACR Annual Meeting
Tags:
Preclinical
Immuno-Oncology
AACR
LEXINGTON, Mass.--(BUSINESS WIRE)--Elpis Biopharmaceuticals, an IND stage biopharmaceutical company developing next generation immunotherapies to transform cancer treatment, today presented two posters at the American Association for Cancer Research (AACR) Annual Meeting, occurring April 8-13, 2022.
“Our pipeline of innovative, multi-functional immunotherapeutics continues to expand and advance, with the goal of addressing the high unmet medical needs of relapse and resistant cancers to current immunotherapies,” says Yan Chen, President and Chief Executive Officer at Elpis Biopharmaceuticals. “We are excited to showcase our latest breakthrough research.”
Discovery of EPIM-001, a tumor targeted engineered IL2 with biased IL2Rβ agonist activities, Poster Number: LB214, Late-Breaking Research: Immunology 2, April 13th 9:00 AM-12:30PM
Key findings from this presentation include:
Development of fully human anti-CD19 and CD22 bispecific tandem CAR-T for the treatment of resistant or relapsed B cell malignancies, Poster Number: LB002, Late-Breaking Research: Clinical Research 1, April 10 1:30 PM-5:00 PM
Key findings from this presentation include:
“We are excited to present the preclinical studies of our two lead programs. EPIM-001, an IND-stage molecule, is a bispecific multi-functional tumor targeting IL2Rβ agonist engineered to selectively activate effector T cells and NK cells, potentially enhancing treatment of a broad range of solid tumors” said Kehao Zhao, Chief Scientific Officer of Elpis Biopharmaceuticals. EPC-001 is a fully human CD19/CD22 bispecific tandem CAR-T candidate currently being studied in an investigator-initiated trial. “We are encouraged by the mechanism of EPC-001 to engage and activate CAR-T cells through bispecific or mono-specific targeting, which indicates it may have the ability to prevent and overcome resistance induced by tumor antigen escape.”
Presentations will be available on Elpis’ website at https://elpisbiopharmaceuticals.com.
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is engineering and developing multifunctional immunotherapies, which modulate disease biology with precision and safety to overcome cancer resistance. Through its proprietary mRNADisTM antibody discovery and mSCAFoldTM protein engineering platforms, Elpis is advancing a rich pipeline to treat solid tumors and hematological malignancies with the goal of improving outcomes for patients with difficult-to-treat and resistant cancers. Elpis is headquartered in Lexington, MA, with research labs in the U.S. and China.
Contacts
Karen Sharma MacDougall ksharma@macdougall.bio 781-235-3060
Karen Sharma MacDougall ksharma@macdougall.bio 781-235-3060
